Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.

@article{Marzi2013AntibodiesAN,
  title={Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.},
  author={Andrea Marzi and Flora Engelmann and Friederike Feldmann and Kristen Haberthur and W. Lesley Shupert and Douglas L Brining and Dana P. Scott and Thomas W. Geisbert and Yoshihiro Kawaoka and Michael G. Katze and Heinz Feldmann and Ilhem Messaoudi},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2013},
  volume={110 5},
  pages={1893-8}
}
Ebola viruses cause hemorrhagic disease in humans and nonhuman primates with high fatality rates. These viruses pose a significant health concern worldwide due to the lack of approved therapeutics and vaccines as well as their potential misuse as bioterrorism agents. Although not licensed for human use, recombinant vesicular stomatitis virus (rVSV) expressing the filovirus glycoprotein (GP) has been shown to protect macaques from Ebola virus and Marburg virus infections, both prophylactically… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 70 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever

  • A Marzi
  • PLoS One 7(4):e36192
  • 2012

Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies

  • X Qiu
  • Sci Transl Med 4(138):138ra181
  • 2012

Similar Papers

Loading similar papers…